PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6) today announced that it is finalizing the developmental transition of its new class of polyphenolic compounds, which possess unique antioxidant and insulin enhancing qualities, distinct from existing classes of drugs for diabetes, to a highly respected, pre-clinical centric laboratory. This will enable PhytoMedical to expedite the pursuit of an Investigational New Drug (IND) application with the FDA, which, if approved, will allow the Company to initiate Phase 1 human studies.
